Thank you to @UrologyTimes for highlighting the health-economic analysis of the ASPIRE Study led by Brett Johnson, MD. The analysis found that the SURE procedure with the CVAC System was associated with an estimated $3,464 in downstream kidney stone–related cost savings per patient over two years compared with standard ureteroscopy. These findings add an important economic perspective to the clinical evidence supporting the benefits of reducing residual stone burden and downstream healthcare utilization. Read the full article: urologytimes.com/view/econom… #NoStoneLeftBehind #KidneyStone #CVACSystem #Calyxo

New evidence reinforces a new, patient-centered standard for assessing efficacy of stone removal procedures. The Journal of Endourology recently published results from the CLEARANCE study and ASPIRE randomized controlled trial evaluating the CVAC System. Key findings include: • 96% mean stone clearance and very low residual stone volume (14.1 mm³)(1) • 73% reduction in unplanned healthcare events* compared with standard ureteroscopy(2) • Residual stone volume, not stone-free rate, was a predictor of long-term outcomes These findings reinforce the importance of minimizing residual stone burden to improve meaningful, long-term patient outcomes. Read the full release: calyxoinc.com/calyxo-news/cv… *ED visits, hospitalizations, and retreatments likely due to residual stones at the end of the procedure References: 1 Eisner BH, et al. J Endourology. 2026. 2.Matlaga BR, et al. J Endourology. 2026. Learn more about the #CVACSystem: calyxoinc.com Safety Info: calyxoinc.com/isi #Urology #NoStoneLeftBehind #MedTech #Calyxo #ClinicalTrial